Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma
Author:
Funder
Amgen
Celgene
Janssen
Pharmacyclics
Amgen Inc
Amgen Inc.
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference91 articles.
1. Multiple myeloma;Kumar;Nat Rev Dis Primers,2017
2. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017
3. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015
4. Current treatment landscape for relapsed and/or refractory multiple myeloma;Dimopoulos;Nat Rev Clin Oncol,2015
5. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States;Song;Curr Med Res Opin,2016
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The role of proteasomes in tumorigenesis;Genes & Diseases;2023-08
2. Integrative transcriptome analysis of SARS-CoV-2 human-infected cells combined with deep learning algorithms identifies two potential cellular targets for the treatment of coronavirus disease;Brazilian Journal of Microbiology;2022-11-26
3. A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors;Journal of Hematology & Oncology;2022-05-07
4. Bone‐Targeted Bortezomib Inhibits Bortezomib‐Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone;Journal of Bone and Mineral Research;2022-01-22
5. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma;Frontiers in Oncology;2021-11-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3